FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904193838> ?p ?o ?g. }

• W2904193838 endingPage "265" @default.
• W2904193838 startingPage "254" @default.
• W2904193838 abstract "Aims: To estimate the impact of anti-vascular endothelial growth factor (VEGF) agents on visual impairment and blindness avoided in patients with diabetic macular edema (DME) and on associated patient and caregiver productivity loss in Japan.Methods: This study compared the impact of current care (estimated at 53.8% utilization of anti-VEGF agents using current data) with that of hypothetical care (characterized by a higher utilization of anti-VEGF agents [80.0%], as estimated by an expert panel) of DME patients. A population-based Markov model (two-eye approach) simulated visual acuity (Early Treatment Diabetic Retinopathy Study [ETDRS] letters) transitions over 5 years with DME treatments (intravitreal aflibercept, ranibizumab, and triamcinolone acetonide, and grid/focal laser) in patients with DME. Patient and caregiver productivity loss was determined using the human capital method.Results: In total, 570,000 DME patients were included in the model over 5 years. Increased utilization of anti-VEGF agents resulted in 6,659 fewer cases of severe visual impairment (SVI; 26–35 ETDRS letters) or blindness (0–25 ETDRS letters) compared with the current care approach (26,023 vs 32,682 cases; 20.38% reduction) over this period. Increased utilization of anti-VEGF agents also contributed to productivity loss savings of ¥12.58 billion (US $115.64 million) (i.e., 17.01%) at the end of year 5. The total overall saving over 5 years was ¥45.83 billion (US $421.27 million) (13.45%).Limitations: Few Japanese data were available, and assumptions were made for some inputs. Vision changes dependent on the function of both eyes were not studied. Only intravitreal (not sub-Tenon’s) injections of triamcinolone were considered in this model. Direct costs were not considered.Conclusions: Increased utilization of anti-VEGF agents can reduce SVI and legal blindness in patients with DME in Japan. This would also be associated with substantial savings in patient and caregiver productivity loss." @default.
• W2904193838 created "2018-12-22" @default.
• W2904193838 creator A5016948580 @default.
• W2904193838 creator A5020407000 @default.
• W2904193838 creator A5038435422 @default.
• W2904193838 creator A5046116530 @default.
• W2904193838 creator A5057830009 @default.
• W2904193838 creator A5072052072 @default.
• W2904193838 date "2019-01-09" @default.
• W2904193838 modified "2023-09-25" @default.
• W2904193838 title "The impact of anti-vascular endothelial growth factor agents on visual impairment/blindness prevention in patients with diabetic macular edema and on associated patient and caregiver burden in Japan" @default.
• W2904193838 cites W1504058728 @default.
• W2904193838 cites W1545259384 @default.
• W2904193838 cites W1915008606 @default.
• W2904193838 cites W1982068990 @default.
• W2904193838 cites W1982553729 @default.
• W2904193838 cites W2001901310 @default.
• W2904193838 cites W2004358584 @default.
• W2904193838 cites W2004955542 @default.
• W2904193838 cites W2011690346 @default.
• W2904193838 cites W2018888303 @default.
• W2904193838 cites W2033522605 @default.
• W2904193838 cites W2037780881 @default.
• W2904193838 cites W2038495425 @default.
• W2904193838 cites W2046099308 @default.
• W2904193838 cites W2050020278 @default.
• W2904193838 cites W2053599523 @default.
• W2904193838 cites W2065125144 @default.
• W2904193838 cites W2072439859 @default.
• W2904193838 cites W2079794035 @default.
• W2904193838 cites W2086592233 @default.
• W2904193838 cites W2093323239 @default.
• W2904193838 cites W2095441798 @default.
• W2904193838 cites W2097132878 @default.
• W2904193838 cites W2103414578 @default.
• W2904193838 cites W2107826392 @default.
• W2904193838 cites W2116525177 @default.
• W2904193838 cites W2161279821 @default.
• W2904193838 cites W2343491610 @default.
• W2904193838 cites W2520946895 @default.
• W2904193838 cites W2534063642 @default.
• W2904193838 cites W2567289819 @default.
• W2904193838 cites W2574755901 @default.
• W2904193838 cites W2767261857 @default.
• W2904193838 cites W2805868637 @default.
• W2904193838 cites W4300052645 @default.
• W2904193838 cites W922383587 @default.
• W2904193838 doi "https://doi.org/10.1080/13696998.2018.1558867" @default.
• W2904193838 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30550375" @default.
• W2904193838 hasPublicationYear "2019" @default.
• W2904193838 type Work @default.
• W2904193838 sameAs 2904193838 @default.
• W2904193838 citedByCount "4" @default.
• W2904193838 countsByYear W29041938382019 @default.
• W2904193838 countsByYear W29041938382020 @default.
• W2904193838 countsByYear W29041938382021 @default.
• W2904193838 crossrefType "journal-article" @default.
• W2904193838 hasAuthorship W2904193838A5016948580 @default.
• W2904193838 hasAuthorship W2904193838A5020407000 @default.
• W2904193838 hasAuthorship W2904193838A5038435422 @default.
• W2904193838 hasAuthorship W2904193838A5046116530 @default.
• W2904193838 hasAuthorship W2904193838A5057830009 @default.
• W2904193838 hasAuthorship W2904193838A5072052072 @default.
• W2904193838 hasConcept C118487528 @default.
• W2904193838 hasConcept C118552586 @default.
• W2904193838 hasConcept C119767625 @default.
• W2904193838 hasConcept C134018914 @default.
• W2904193838 hasConcept C141071460 @default.
• W2904193838 hasConcept C2776694085 @default.
• W2904193838 hasConcept C2777802072 @default.
• W2904193838 hasConcept C2778257484 @default.
• W2904193838 hasConcept C2778749236 @default.
• W2904193838 hasConcept C2778903070 @default.
• W2904193838 hasConcept C2779829184 @default.
• W2904193838 hasConcept C2780347916 @default.
• W2904193838 hasConcept C2781100027 @default.
• W2904193838 hasConcept C2781372952 @default.
• W2904193838 hasConcept C2908647359 @default.
• W2904193838 hasConcept C555293320 @default.
• W2904193838 hasConcept C71924100 @default.
• W2904193838 hasConcept C99454951 @default.
• W2904193838 hasConceptScore W2904193838C118487528 @default.
• W2904193838 hasConceptScore W2904193838C118552586 @default.
• W2904193838 hasConceptScore W2904193838C119767625 @default.
• W2904193838 hasConceptScore W2904193838C134018914 @default.
• W2904193838 hasConceptScore W2904193838C141071460 @default.
• W2904193838 hasConceptScore W2904193838C2776694085 @default.
• W2904193838 hasConceptScore W2904193838C2777802072 @default.
• W2904193838 hasConceptScore W2904193838C2778257484 @default.
• W2904193838 hasConceptScore W2904193838C2778749236 @default.
• W2904193838 hasConceptScore W2904193838C2778903070 @default.
• W2904193838 hasConceptScore W2904193838C2779829184 @default.
• W2904193838 hasConceptScore W2904193838C2780347916 @default.
• W2904193838 hasConceptScore W2904193838C2781100027 @default.
• W2904193838 hasConceptScore W2904193838C2781372952 @default.
• W2904193838 hasConceptScore W2904193838C2908647359 @default.
• W2904193838 hasConceptScore W2904193838C555293320 @default.
• W2904193838 hasConceptScore W2904193838C71924100 @default.

• next